NCT03295227View on ClinicalTrials.gov

Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

December 6, 2017

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Stage III Thymoma AJCC v8Stage IIIA Thymoma AJCC v8Stage IIIB Thymoma AJCC v8Stage IV Thymoma AJCC v8Stage IVA Thymoma AJCC v8Stage IVB Thymoma AJCC v8Unresectable Thymic Carcinoma
Interventions
BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER